Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma

Author: Kast R.  

Publisher: Springer Publishing Company

ISSN: 0167-594X

Source: Journal of Neuro-Oncology, Vol.94, Iss.2, 2009-09, pp. : 163-167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract